1. Market Research
  2. > Pharmaceutical
  3. > Drug Delivery Market Trends
  4. > Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts

Targeted Drug Delivery Partnering 2010-2016 report provides understanding and access to the targeted drug delivery partnering deals and agreements entered into by the world’s leading healthcare companies.

Trends in targeted drug delivery partnering deals
Top targeted drug delivery deals by value
Deals listed by company A-Z, deal type, stage of development, therapy type

This report provides details of the latest Targeted Drug Delivery agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review Targeted Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Targeted Drug Delivery partnering deals.

The report presents financial deal term values for Targeted Drug Delivery deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Targeted Drug Delivery partnering field; both the leading deal values and most active Targeted Drug Delivery dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 160 online deal records of actual Targeted Drug Delivery deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Targeted Drug Delivery dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Targeted Drug Delivery dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Targeted Drug Delivery deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Targeted Drug Delivery dealmaking with a brief summary followed by a comprehensive listing of Targeted Drug Delivery deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Targeted Drug Delivery partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Targeted Drug Delivery partnering deals signed and announced since Jan 2010. The chapter is organized by specific Targeted Drug Delivery technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Targeted Drug Delivery partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Targeted Drug Delivery partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Targeted Drug Delivery technologies and products.


Key benefits

Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts provides the reader with the following
Key benefits:

In-depth understanding of Targeted Drug Delivery deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Targeted Drug Delivery agreements with numerous real life case studies
Detailed access to actual Targeted Drug Delivery contracts entered into by leading biopharma companies
Identify most active Targeted Drug Delivery dealmakers since 2010
Insight into terms included in a Targeted Drug Delivery partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope

Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Targeted Drug Delivery trends and structure of deals entered into by leading companies worldwide.

Targeted Drug Delivery Partnering Terms and Agreements includes:

Trends in Targeted Drug Delivery dealmaking in the biopharma industry since 2010
Analysis of Targeted Drug Delivery deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Targeted Drug Delivery deals
Access to Targeted Drug Delivery contract documents
Leading Targeted Drug Delivery deals by value since 2010
Most active Targeted Drug Delivery dealmakers since 2010

In Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 160 Targeted Drug Delivery deals.


Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Table Of Contents

Global Targeted Drug Delivery Partnering 2010-2016: Deal trends, players, financials and forecasts
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Targeted Drug Delivery dealmaking

2.1. Introduction
2.2. Targeted Drug Delivery partnering over the years
2.3. Most active Targeted Drug Delivery dealmakers
2.4. Targeted Drug Delivery partnering by deal type
2.5. Targeted Drug Delivery partnering by therapy area
2.6. Deal terms for Targeted Drug Delivery partnering
2.6.1 Targeted Drug Delivery partnering headline values
2.6.2 Targeted Drug Delivery deal upfront payments7
2.6.3 Targeted Drug Delivery deal milestone payments
2.6.4 Targeted Drug Delivery royalty rates

Chapter 3 - Leading Targeted Drug Delivery deals

3.1. Introduction
3.2. Top Targeted Drug Delivery deals by value

Chapter 4 - Most active Targeted Drug Delivery dealmakers

4.1. Introduction
4.2. Most active Targeted Drug Delivery dealmakers
4.3. Most active Targeted Drug Delivery partnering company profiles

Chapter 5 - Targeted Drug Delivery contracts dealmaking directory

5.1. Introduction
5.2. Targeted Drug Delivery contracts dealmaking directory

Chapter 6 - Targeted Drug Delivery dealmaking by technology type

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Targeted Drug Delivery deals by company A-Z

Appendix 2 - Targeted Drug Delivery deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation

Appendix 3 - Targeted Drug Delivery deals by deal type

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative RandD
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty

Appendix 4 - Targeted Drug Delivery deals by therapy area

Appendix 5 -Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering


Table of figures

Figure 1: Targeted Drug Delivery partnering since 2010
Figure 2: Active Targeted Drug Delivery dealmaking activity- 2010 to 2016
Figure 3: Targeted Drug Delivery partnering by deal type since 2010
Figure 4: Targeted Drug Delivery partnering by disease type since 2010
Figure 5: Targeted Drug Delivery deals with a headline value
Figure 6: Targeted Drug Delivery deals with an upfront value
Figure 7: Targeted Drug Delivery deals with a milestone value
Figure 8: Targeted Drug Delivery deals with a royalty rate value
Figure 9: Top Targeted Drug Delivery deals by value since 2010
Figure 10: Most active Targeted Drug Delivery dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
European Market Report for Peripheral Intravenous Catheters 2017 - MedCore

European Market Report for Peripheral Intravenous Catheters 2017 - MedCore

  • $ 6495
  • Industry report
  • November 2016
  • by iData Research, Inc.

Description The European PIVC market includes three segments: conventional PIVCs, safety PIVCs and midlines. The safety PIVC segment includes three sub-segments: active safety PIVCs, passive safety PIVCs ...

North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

North American Drug Delivery Technologies Market by Route of Administration, Pulmonary, Injectable, Ocular, Nasal, Topical, Implantable), End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The North American drug delivery technologies market is projected to reach USD 758.7 billion by 2021 from USD 520.0 billion in 2016, at a CAGR of 6.5% during the forecast period. Major factors contributing ...

Syringes Market by Usability & Disposable Syringes), Material, Type - Global Forecast to 2021

Syringes Market by Usability & Disposable Syringes), Material, Type - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The syringes market is expected to reach USD 15.99 billion by 2021, at a CAGR of 8.7% from 2016 to 2021. The syringes market is primarily driven by the high prevalence of chronic diseases across the globe. ...

Global Polymeric Foams Industry

October 2016 $ 4950

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.